CN1087272A - A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease - Google Patents
A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease Download PDFInfo
- Publication number
- CN1087272A CN1087272A CN 92114065 CN92114065A CN1087272A CN 1087272 A CN1087272 A CN 1087272A CN 92114065 CN92114065 CN 92114065 CN 92114065 A CN92114065 A CN 92114065A CN 1087272 A CN1087272 A CN 1087272A
- Authority
- CN
- China
- Prior art keywords
- radix
- present
- powder medicine
- treatment
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to treat the Chinese powder medicine capsule of chronic ischemic heart disease, it is characterized in that pure Chinese powder medicine is a Radix Ginseng 2-5%, the Radix Astragali 22-26%, Radix Notoginseng 1-3%, Flos Carthami 10-14%, Rhizoma Corydalis 10-14%, Radix Salviae Miltiorrhizae 22-26%, Lignum Santali Albi 6-10%, Semen Alpiniae Katsumadai 10-14%, Styrax 0.6-1.0%, Borneolum Syntheticum 0.06-0.10%, Mentholum 0.02-0.06%.The present invention is applicable to the chronic outbreak of ischemic heart desease and the after treatment after the acute attack, guarantee the heart normal function, effect is remarkable, can prolong disease cycle, reduce the morbidity number of times, alleviate disease symptom, clinical practice proof total effective rate reaches 93%, but human body immunity improving power, the collection treatment is one with prevention.
Description
The present invention relates to a kind of treatment chronic ischemic heart disease, specifically be applicable to the Chinese herbal medicine powder capsule of the after treatment after cardiopathic chronic outbreak and the acute attack.
At present, along with developing rapidly of Chinese national economy, people's rhythm of life is accelerated day by day, build the ultra-long time work of the moon all the year round, and along with growth in the living standard, the acceleration of social population's senescence, cardiovascular diseases's sickness rate is also more and more higher, and external cardiopathic patient's number also accounts for first of various number of the infecteds all the time.The cardiovascular diseases is worldwide commonly encountered diseases, frequently-occurring disease, so the research treatment is cardiopathic also a lot, clinical medicine such as Pan Xianding, nitroglycerin etc. have been used for, the treatment characteristics are that the speed of taking effect is fast, and are outstanding to acute patient's remission curative effect, had as Riboflavin Tetrabutyrate, metoprolol in recent years again, that distressed medicine such as fixed applies to the cardiovascular diseases in succession is clinical, and be mainly used in diseases such as angina pectoris, its effect is also better, and chemical drugs generally is used for acute patient more, and certain side effect is arranged.Aspect Chinese patent medicine, be used for heart acute disease clinical as SUXIAO JIUXIN DAN, Styrax Pilulae, coronary disease Styrax Pilulae, the main armaticity medical material that uses in this class medicine composition, has happy key, the effect of the mind of waking up, instant effect, effect are also better, but its effect is of short duration, cost an arm and a leg, be not suitable for the chronic heart disease patient and use.The medicine that is used for chronic ischemic heart disease that some are common, as Radix Salviae Miltiorrhizae Tabellae and injection, curative effect such as FUFANG DANSHEN PIAN and injection is limited, new drug in recent years is used for clinical in haydan capsule, DIAOXINXUE KANG, comfortable, heart treasured etc., rare expensive animals and plants are arranged, as the toad Moschus moschiferous in the prescription that these new drugs have.Contain Calculus Bovis, Moschus, Cornu Cervi Pantotrichum etc. in pills for curing heart disease and the heart treasured, and Flos Daturae one class there is certain toxic Chinese crude drug, also has some Chinese patent medicines only early rich at treatment, or the treatment arrhythmia etc., applicable surface is too narrow again.
The purpose of this invention is to provide that a kind of Chinese medicine thinks to deficiency of heart-QI, flaccidity of the heart-yang, so that QI stagnated by cold, blood stasis and the turbid obstruction of expectorant cause heart arteries and veins obstructed, chest paralysis heart pain, and the myocardial ischemia thought of western medicine, the angina pectoris that anoxia caused, the hard plug of cardiac muscle waits the Chinese patent medicine of treatment usefulness, specifically be applicable to the chronic outbreak of ischemic heart desease and the after treatment after the acute attack, be based on guaranteeing the heart normal function after the heart attack.And the drug prescription Chinese medicine property of medicine is gentle, does not contain rare costliness and virose Chinese crude drug.Take no toxicity for a long time, can increase body's immunity.
The present invention adopts modern capsule for medicine, and Chinese powder medicine prescription and percentage by weight in the capsule are:
Radix Ginseng 2-5%, Radix Astragali 22-26%, Radix Notoginseng 1-3%, Flos Carthami 10-14%, Rhizoma Corydalis 10-14%, Radix Salviae Miltiorrhizae 22-26%, Lignum Santali Albi 6-10%, Semen Alpiniae Katsumadai 10-14%, Styrax 0.6-1.0%, Borneolum Syntheticum 0.06-0.10%, Mentholum 0.02-0.06%.
Chest paralysis heart pain also is an ischemic heart desease, its cardinal symptom for nervous, uncomfortable in chest, chest pain, breathe hard, be the modal frequently-occurring disease of mid-aged population, think according to Chinese medical theory and clinical practice, the basic pathology characteristics of coronary heart disease are " deficiency in origin and excess in superficiality ", " overabundance of pathogen causing excess syndrome, lack of vital essence resulting in deficiency syndrome " is according to this dialectical Thoughts, the deficiency in origin of coronary heart disease is meant the whole body insufficiency of vital energy and blood based on heart, the negative and positive weakness, " mark is real " is meant qi depression to blood stasis on the basis of deficiency in origin, stagnation of phlegm-damp." deficiency in origin " all can cause malnutrition of heart blood with " mark real ", heart arteries and veins impatency and cause nervous, uncomfortable in chest, breathe hard, painedly be the systemic disease of cardinal symptom, should be so treat ischemic heart desease with Qi-benefiting and heart-nourishing, disperse blood stasis and dredge collateral, the chest stuffiness relieving method of treatment of reducing phlegm is an aim.According to the basic pathology of coronary heart disease " deficiency in origin and excess in superficiality " and the pathological characteristic of modern medicine coronary atherosclerosis and spasm, the starting point of treatment is to increase coronary flow, increase the supply of blood flow amount of cardiac muscular tissue, the person reduces myocardial oxygen consumption in addition, improves hypoxia-bearing capability to correct cardiac muscle to the confession of blood oxygen and the balance-loss state of need.So Radix Ginseng, the Radix Astragali are monarch in the prescription of the present invention, consolidate with reinforcing the heart gas, handsome blood operation helps QI regulating medicine to increase the blood stasis dispelling ability.Radix Notoginseng is promoting blood circulation and hemostasis then, and repercussive is in arteries and veins, and promoting the circulation of blood is outside arteries and veins.Blood system falls clearly in Radix Salviae Miltiorrhizae bitter in the mouth cold nature, energy clearing away heat and cooling blood, eliminating blood stasis to promote regeneration of blood.But the gas in the Rhizoma Corydalis promoting the circulation of blood, the blood in the gas can be smooth with hot warm in nature can a surname with QI and blood of gas, and the fragrant row of acrid in the mouth looses.Flos Carthami is gone into the heart, liver two through blood system, and Xin Xianghang is diffusing, and sweet gentleness is smooth, so above four flavors are minister, Lignum Santali Albi, Styrax, Semen Alpiniae Katsumadai phase 5 act on heart spleen for assistant simultaneously, with the blood in regulating the flow of vital energy, help the blood operation, and blood stasis dispellingization stagnates.Borneolum Syntheticum eliminating cold for resuscitation thinking is treated pained.Mentholum waking up the patient from unconsciousness by clearing away heat thinking, the refresh oneself, soothing liver-QI is strongly fragrant and pain relieving is messenger drug altogether, and the two joins Styrax removing dampness eliminating phlegm, and is vexed to separate brain, breathes hard.The medicine of below respectively distinguishing the flavor of rises altogether and gets final product the beneficial motive, happy key, blood stasis dispersing and phlegm expelling, the effect of removing obstruction in the collateral to relieve pain.All medicines match and complement each other, and are scientific and reasonable, guarantee the curative effect of medicine.
The present invention not only is consistent with China theory of medicine, and also be consistent with modern scientific theory, we are according to Ministry of Health of the People's Republic of China's provisions for new drugs approval pertinent regulations, successively having done the several experiments relevant with pharmacodynamics of the present invention with rabbit, Cavia porcellus, rat and mice, is matched group with the compound Salviae Miltiorrhizae.
Table 1 the present invention is to the influence of normal guinea pig coronary flow
Experimental result shows that the present invention of two kinds of dosage and compound Salviae Miltiorrhizae all significantly increase the coronary flow of guinea pig isolated heart, and heavy dose of of the present invention group effect is better than isodose compound Salviae Miltiorrhizae group.
The arteria coronaria that table 2 the present invention causes pituitrin
The influence of the heart coronary flow that flow reduces
Table 3 the present invention is to the influence of mice hypoxia endurance time
Above experimental result shows, oral still intraperitoneal injection no matter, and the present invention of three groups of various dose can significantly prolong the mice hypoxia endurance time, and effect of the present invention is better than isodose compound Salviae Miltiorrhizae group.
Experimental result shows, the present invention can reduce the viscosity of the high viscosity blood of rabbit due to the macromolecule right rotary glycoside significantly, six of whole blood viscosity different cut speed and two different cutting in the speed of blood plasma, low shear rate has significant difference, high shear rate has significant differences.The present invention can also shorten the time of erythrocyte electrophoresis, and packed cell volume is reduced.
Table 9 the present invention to coronary ligation after the ST field offset influence relatively
＊P＜0.05 ＊＊P＜0.01
Table 10 the present invention to coronary ligation after abnormality Q wave the influence of number appears
Experimental result shows that normal saline group electrocardiogram is cut back 2hr at knot, and the T wave height is alarmmed, and the ST section is raised all clearly, and big small dose group of the present invention and compound Salviae Miltiorrhizae group all are lower than the normal saline group significantly.The ST section is raised total Bo voltage as seen from Table 9, the ST section is raised unusually and is reduced total meansigma methods that number and ST field offset take place and ST field offset divided by whole meansigma methodss of mapping points, small dose group of the present invention all is lower than the normal saline group, and wherein 24hr reduces significant difference (p＜0.05).And the heavy dose of group of the present invention and all remarkable, and heavy dose of of the present invention group of 24hr difference highly significant (p＜0.01) with the compound Salviae Miltiorrhizae group and the normal saline group comparing difference of dosage.
By table 10,11 as seen: number of times that of the present invention group and compound Salviae Miltiorrhizae group pathologic Q ripple occur after the ligation and myocardial infarction NBT dyeing back weighing and normal saline group more all are lower than physiological water salt group.Heavy dose wherein of the present invention and compound Salviae Miltiorrhizae group are compared with the normal saline group all has significant difference (p＜0.05).
In above experimental result, NST, Σ ST/NST are lower than the normal saline group proves that the present invention has the effect of alleviating to the degree and the scope of the myocardial ischemic injury of rabbit experiment.The minimizing of NST, Q ripple and NBT dyeing explanation the present invention and compound Salviae Miltiorrhizae all have the scope of dwindling the myocardial infarction that causes after the hat anterior descending branch ligation of a rabbit left side.And action time of the present invention is lasting than the compound Salviae Miltiorrhizae group.
Acute toxicity test of the present invention is by existing test method, and situation is as follows:
One, mouse stomach medicine-feeding test:
Select 30 of the mices of body weight 20 ± 2g for use, male and female are supported usefulness, and fasting 12 hours is divided into matched group (10), administration group (20) at random.The administration group 4 times on the one, amounts to 50g/kg/ day with the suspension oral gavage of the present invention of the maximum volume (0.5ml/10g) of Cmax (25%).Matched group is irritated stomach with the equal-volume normal saline.Raised and observe seven under about 20 ℃ of room temperatures after the administration, beginning animal food-intake is less slightly, recovers normal two days later, drinking-water, activity.All no abnormal phenomenon such as body weight, hair color etc. is put to death organs such as the animal perusal heart, liver, spleen, lung, kidney, relatively has no significant change with matched group.So the dosis tolerata of mice is 50g/kg, obtains the dosis tolerata multiple of mice by following formula.
The dosis tolerata multiple of mice=(every mouse tolerance dose)/(mice average weight) * (adult's average weight (60,000g))/(adult's consumption every day)
The dosis tolerata of mice is 750 times of people's consumption.
Two, mouse peritoneal drug administration by injection test
Get 50 of mices earlier, male and female half and half are divided into 5 groups at random, every group 10, with five dosage lumbar injection extracting solution of the present invention, feeding conditions is with irritating the stomach group, the performance of injection rear section mice is quiet, has the part mice to begin death after 7 hours, its phenomenon finding during with prerun.After the medication 24 hours, death no longer takes place in the mice of survival, and survival mice was recovered normally to look for food etc. movable after 1 to 3 day, continues to observe to the 7th day none death.The mice of death was dissected in half an hour, see intestinal tube and near organize slightly hyperemia and minute quantity to be dispersed in the petechia, other internal organs naked eyes show no obvious abnormalities.Dissect the mice that survived in the 7th day after the medication, the finding of naked eye of its heart, liver, kidney, lung, stomach, identical with the mice of not medication, the results are shown in Table 1.
Table 12 L of the present invention
D50Mensuration (lumbar injection)
i＝0.0757
Adopt the simplification probit method to try to achieve the median lethal dose(LD 50) of mouse peritoneal injection of the present invention according to the mouse death rate of respectively organizing behind lumbar injection the present invention:
Be L
D50=20.3823 g/kg
L
D5095% average fiducial limit=20.3823 ± 1.0359 g/kg
Rat body weight (g) change list before and after table 13 administration of the present invention
* secondary is determined as 20 before the middle dosage group, is 19 later on;
First three time of * matched group is determined as 20, is 18 later on.
By in above four tables as can be seen, though hemoglobin, RBC number, leukocyte count and platelet fluctuate, all within range of normal value, the also no abnormal variation of the measurement result of leukocyte differential count.Prompting the present invention does not have bad influence to hemopoietic system and surrounding hemogram.
Table 18 the present invention is to the influence of rat serum total protein
* suffer from the otitis media deselect because of a rat;
* has two because of suffering from the otitis media deselect.
Table 19 the present invention is to the albuminous influence of rat serum
〉
Above experimental result shows that each is organized serum glutamic pyruvic transminase, total protein, albumin, globulin, the blood urea nitrogen of administration animal and compares no significant difference with matched group.Other detects jaundice index between 2-5, and thymol all between 1-5, this shows that the present invention does not have overt toxicity to the hepatic and renal function of rat.
Three, tissue slice is observed
After the drug withdrawal, rat divides that two batches of execution (at interval two weeks) are cored, liver,spleen,kidney, stomach, lung, with formaldehyde fixed HE dyeing, carries out tissue slice under 400 power microscopes and observes.First heart, liver, spleen, lung, kidney, the overwhelming majority of stomach texture all belong to normal structure as a result.One example is only arranged, heavy dose of group slight hepatic cell cloudy swelling, heavy dose of group and matched group respectively have a routine bronchial chronic inflammation to change.The animal of second batch of execution only has a routine matched group that the pathological change of chronic bronchitis is arranged, and other tissue slice is normally.
Show that from each time result of the test of above long term toxicity test of the present invention the present invention does not influence the normal growth growth of rat and the normal growth of body weight; The every index of peripheral hemogram is normally, and prompting does not influence the hemopoietic function of rat; Do not reduce liver, stomach function.Behind the sacrifice of animal, the size of the perusal heart, liver, spleen, lung, kidney, stomach, surface and hardness are all no abnormal.Tissue slice checks that the heart, spleen, kidney, all no abnormal pathologic of stomach four internal organs officials change.Only there is first to put to death the heavy dose of group of animal hepatocyte slight cloudy swelling is arranged, second batch of no abnormal pathological changes, prompting the present invention crosses heavy dose of Time and can cause reversible slight poisoning.The heavy dose of example of the rat of first execution, matched group two examples have the chronic bronchitis reason to change.This is owing to stop sending in raising due to heating installation catches a cold.More than explanation the present invention is a Chinese patent medicine that safety is big, toxicity is little.
Clinical observation of the present invention, " the national coronary heart disease opinion take stopgap measures standard " of working out with reference to China on tcm diagnosis and the typing and " angina pectoris Chinese medical discrimination tentative standard ", and clinical practice experience, differentiation of symptoms and signs for classification of syndrome, be divided into four kinds of deficiency of both QI and YIN, qi stagnation and blood stasis type, type of stagnation of phlegm-damp, mixed type, and in the clinical practice, simple type is less, and compound is many.And, reach related standards and carry out efficacy evaluation according to " angina pectoris and ECG curative effect evaluation criteria " that China works out.By clinical observation checking, the type of deficiency of both QI and YIN produce effects be 62.5%, effectively be 37.5%, the qi stagnation and blood stasis type produce effects be 100%, the type of stagnation of phlegm-damp produce effects be 66.67%, effectively be 33.33%, the mixed type produce effects is 82.75%, effectively is 17.24%.Simultaneously from above four types as can be seen total effective rate be 100%, through using the hypergeometry probability calculation, P＜0.05, further carrying out per two groups compares, significant difference P＜0.05 is arranged between type of deficiency of both QI and YIN and the qi stagnation and blood stasis type, and all the other per two groups are compared difference that there are no significant, P＞0.05 illustrates in " ischemic heart desease " traditional Chinese medical science typing best with the qi stagnation and blood stasis type curative effect.
Table 23 62 examples " ischemic heart desease " traditional Chinese medical science typing curative effect relatively
The symptom size scale before and after the table 24 ischemic heart desease patient treatment
By table 24 as seen, the present invention to " ischemic heart desease " patient nervous, uncomfortable in chest, breathe hard, angina pectoris, heart failure, abnormality T wave, S-T ↓ etc. symptom all improve significantly, before and after the treatment size scale, x
2Check, P＜0.005, wherein remarkable to breathe hard, P＜0.05 has highly significant difference.
The present invention can be a year and a half in normal temperature condition following storage period, and its character, discriminating, content, moisture all fluctuate in acceptability limit.
Chinese powder medicine prescription in the capsule of the present invention, it presses the property classification of Chinese medicine, and available one or more other Chinese crude drugs with quasi-medicated property substitute, can substitute the in like manner Radix Astragali and Rhizoma Polygonati, Radix Notoginseng and Pseudobulbus Bletillae (Rhizoma Bletillae) with Radix Codonopsis such as Radix Ginseng, Flos Carthami and Semen Persicae, Rhizoma Corydalis and Radix Curcumae, Radix Salviae Miltiorrhizae and Rhizoma Chuanxiong, Lignum Santali Albi and Lignum Dalbergiae Odoriferae, Semen Alpiniae Katsumadai and Fructus Amomi, Styrax and Benzoinum, Borneolum Syntheticum and Rhizoma Acori Graminei, all interchangeable replacement of Mentholum and Herba Menthae.
Chinese powder medicine in every capsules of the present invention weighs 0.4 gram, and the ischemic heart patient takes 2 to 4 at every turn, every day three times or follow the doctor's advice.
Powder prescription in the capsule of the present invention can be used for tablet, pill, decoction, electuary, oral liquor and other types of formulations simultaneously.
The present invention stipulates according to Pharmacopoeia of People's Republic of China, carries out the formulation of the quality standard of method for making, discriminating, inspection one by one, has augmented content assaying method simultaneously.
Advantage of the present invention is to have benefiting QI and nourishing blood to have one's ideas straightened out, the effect of blood-activating analgetic is applicable to the chronic outbreak of ischemic heart desease and the after treatment after the acute attack, guarantees the heart normal function, effect is remarkable, can prolong disease cycle, reduce the morbidity number of times, alleviate disease symptom, clinical practice proof total effective rate reaches 93%, taking no toxicity for a long time, and the function of human body immunity improving power is arranged, is that the collection treatment is the good medicine of one with prevention.The present invention does not contain the animals and plants of rare costliness, does not contain virose Chinese crude drug yet, and is with low cost, and taking convenience is easy to be accepted by society.
Embodiment one:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Its method for making is earlier Rhizoma Corydalis to be soaked with 0.5% HCI, acid immersion after the immersion is neutralized into neutral immersion (1) with NaOH solution, medicinal residues after the immersion of Rhizoma Corydalis are incorporated Radix Salviae Miltiorrhizae, the Radix Astragali, Flos Carthami mixing back decocting into, fry in shallow oil after-filtration, filtrate is mixed with neutral immersion (1) again, mixed solution is through being condensed into the thick paste shape, mix mutually with Radix Ginseng, Radix Notoginseng, Semen Alpiniae Katsumadai, Lignum Santali Albi fine powder after crushed again and mix thoroughly, and drying is pulverized, add the alcoholic solution of Styrax, Borneolum Syntheticum, Mentholum again and mix thoroughly semi-finished product, with the semi-finished product filling in capsule finished product.
Embodiment two:
Radix Codonopsis 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment three:
Radix Ginseng 4.01%, Rhizoma Polygonati 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment four:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Pseudobulbus Bletillae (Rhizoma Bletillae) 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 0.04%.
Embodiment five:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Semen Persicae 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment six:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Radix Curcumae 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment seven:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Rhizoma Chuanxiong 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment eight:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Dalbergiae Odoriferae 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment nine:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Fructus Amomi 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment ten:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Benzoinum 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Embodiment 11:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Rhizoma Acori Graminei 0.08%, Mentholum 1.04%.
Embodiment 12:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 1.20%, Borneolum Syntheticum 0.08%, Mentholum 1.04%.
Fig. 1 is that acute toxicity test of the present invention is by existing test method, " the coordinate curve chart of rat body weight (g) change list before and after the administration of the present invention; wherein ordinate is represented the weight of animals (g); the time (natural law) that on behalf of animal, abscissa take medicine; under identical conditions is raised the situation of change of observing administration group (three dosage) and matched group body weight after 75 days to second mouse peritoneal drug administration by injection test invading the exterior 13.
Claims (2)
1, a kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease includes capsule for medicine and forms, and it is characterized in that Chinese powder medicine prescription and the percentage by weight in the capsule is:
Radix Ginseng 2-5%, Radix Astragali 22-26%, Radix Notoginseng 1-3%, Flos Carthami 10-14%, Rhizoma Corydalis 10-14%, Radix Salviae Miltiorrhizae 22-26%, Lignum Santali Albi 6-10%, Semen Alpiniae Katsumadai 10-14%, Styrax 0.6-1.0%, Borneolum Syntheticum 0.06-0.10%, Mentholum 0.02-0.06%.
2, a kind of Chinese powder medicine capsule according to claim 1 is characterized in that Chinese powder medicine best prescription and the percentage by weight in the capsule is:
Radix Ginseng 4.01%, the Radix Astragali 24.01%, Radix Notoginseng 2.04%, Flos Carthami 12.03%, Rhizoma Corydalis 12.03%, Radix Salviae Miltiorrhizae 24.06%, Lignum Santali Albi 8.02%, Semen Alpiniae Katsumadai 12.03%, Styrax 0.80%, Borneolum Syntheticum 0.08%, Mentholum 0.04%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92114065 CN1087272A (en) | 1992-11-28 | 1992-11-28 | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92114065 CN1087272A (en) | 1992-11-28 | 1992-11-28 | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1087272A true CN1087272A (en) | 1994-06-01 |
Family
ID=4946778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 92114065 Pending CN1087272A (en) | 1992-11-28 | 1992-11-28 | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1087272A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049139C (en) * | 1994-12-14 | 2000-02-09 | 周喜金 | Application 'Xintie'an' of curing heart disease and preparing process thereof |
| CN1316988C (en) * | 2005-04-21 | 2007-05-23 | 张继成 | Heart disease treating Chinese medicine composition |
| CN100444890C (en) * | 2004-11-04 | 2008-12-24 | 苗毅韧 | Chinese medicinal formulation for restoring cardiac muscle function and adjusting blood pressure and preparation method thereof |
| CN101085018B (en) * | 2006-06-08 | 2012-01-04 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root, notoginseng, radix astragali and borneol or storax and its preparation |
| CN101085021B (en) * | 2006-06-08 | 2012-01-04 | 天津天士力制药股份有限公司 | Medicinal composition containing safflower and radix astragali, preparation method and preparation |
| CN102600420A (en) * | 2012-04-01 | 2012-07-25 | 李承平 | Medicine composition for blood stasis and qi stagnation |
| CN103006842A (en) * | 2012-12-09 | 2013-04-03 | 毛顺卿 | Drug for treatment of traditional Chinese medicine chest stuffiness and pains |
-
1992
- 1992-11-28 CN CN 92114065 patent/CN1087272A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049139C (en) * | 1994-12-14 | 2000-02-09 | 周喜金 | Application 'Xintie'an' of curing heart disease and preparing process thereof |
| CN100444890C (en) * | 2004-11-04 | 2008-12-24 | 苗毅韧 | Chinese medicinal formulation for restoring cardiac muscle function and adjusting blood pressure and preparation method thereof |
| CN1316988C (en) * | 2005-04-21 | 2007-05-23 | 张继成 | Heart disease treating Chinese medicine composition |
| CN101085018B (en) * | 2006-06-08 | 2012-01-04 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root, notoginseng, radix astragali and borneol or storax and its preparation |
| CN101085021B (en) * | 2006-06-08 | 2012-01-04 | 天津天士力制药股份有限公司 | Medicinal composition containing safflower and radix astragali, preparation method and preparation |
| CN102600420A (en) * | 2012-04-01 | 2012-07-25 | 李承平 | Medicine composition for blood stasis and qi stagnation |
| CN103006842A (en) * | 2012-12-09 | 2013-04-03 | 毛顺卿 | Drug for treatment of traditional Chinese medicine chest stuffiness and pains |
| CN103006842B (en) * | 2012-12-09 | 2014-03-05 | 毛顺卿 | Drug for treatment of traditional Chinese medicine chest stuffiness and pains |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1107359A (en) | Galenic composition | |
| CN116898897B (en) | Primordial qi-tonifying, hypoxia-resisting and chronic fatigue-conditioning primordial qi-preserving soup recipe and preparation method thereof | |
| CN1087272A (en) | A kind of Chinese powder medicine capsule that is used for the treatment of chronic ischemic heart disease | |
| CN1698869A (en) | Mind easing oral liquor with gen-seng and lily bulb | |
| CN1041494C (en) | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN103230457B (en) | A kind of Chinese medicine composition treating viral myocarditis and preparation method thereof and purposes | |
| CN113209218B (en) | Traditional Chinese medicine composition for treating ventricular premature beat of children and application thereof | |
| CN108935694A (en) | A kind of healthcare goat milk powder and preparation method thereof with antifatigue simultaneous void of enriching blood | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1053111C (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN1442195A (en) | Medicine for treating child multiacting disease and its preparation method | |
| CN1255147C (en) | Oral liquid for preserving one's longevity | |
| CN1772177A (en) | Orally taken medicine for treating climacteric xerophthalmia and its prepn | |
| CN104147335A (en) | Traditional Chinese medicine preparation for treating thoracic obstruction | |
| CN102266519A (en) | Chinese medicinal composition for treating tuberculosis and preparation method thereof | |
| CN1293971A (en) | Medicine for treating apoplexy and its preparing process | |
| CN1242766C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN1634206A (en) | Capsule for treating heart palpitation | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN1183933C (en) | Medicine for treating incomplete kidney function and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |